According to a recent study, women who undergo radiotherapy treatment for breast cancer have a small but significantly increased risk of developing a primary lung tumor following treatment, to which further research has confirmed that this risk increases with the amount of radiation absorbed by the tissue over time.
The study’s findings were presented by Dr Trine Grantzau, M.D., at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna: "We found that for each Gray delivered to the lung as part of radiotherapy for a breast tumor, the relative risk of developing a subsequent primary lung cancer increased. This increased risk was similar to the reported increased risk of heart disease after radiotherapy for breast cancer.”
"Our findings suggest that any reduction in the dose of radiation to the lung would result in a reduction in the risk of radiation-induced subsequent lung cancers. With the advances in breast cancer treatment and the introduction of breast cancer screening, a growing number of women are becoming long-term survivors, and so we need to have an increased awareness of treatment-induced second cancers and take steps to reduce those risks by using radiotherapy techniques that spare normal tissue as much as possible."
Grantzau, who is a doctor in the department of experimental clinical oncology at Aarhus University Hospital , Aarhus, Denmark, and her colleagues examined the occurrence of second primary lung cancers, a new lung cancer and not a secondary tumor that has spread from the original breast cancer, in a group of 23,627 women in Denmark who had been treated with post-operative radiotherapy for early breast cancer between 1982 and 2007. Among this large group of women, 151 (0.6%) were diagnosed with a new lung cancer (the case group) and were matched with 443 women who had not developed lung cancer (the control group).
A prior study including the 23,627 irradiated women and, additionally, 22,549 unirradiated breast cancer patients, results showed that the risk of developing a radiation-induced second lung cancer was around one in every 200 women treated with postoperative radiotherapy.
"In the current study, we wanted to see if there was a dose-response correlation for second primary lung cancer after breast cancer irradiation. We further wished to estimate the excess relative risk per delivered Gray to the lung. As smoking is strongly correlated to lung cancer, we also looked into the effect of radiation and smoking," explained Grantzau.
The researchers attained radiotherapy records of the previous breast cancer radiation treatment, including the delivered dose, field size and treatment technique, together with the smoking habits for all cases and controls. For the case group they also acquired radiographic images of the lung cancers. With this data they were able to recreate the ways that the women had been treated for the original breast cancer and to determine the amount of radiation that was delivered to the part of the lung where the tumour subsequently developed. They tested the accuracy of their calculated radiation doses on a model, or "phantom", and made the necessary adjustments to take into consideration the higher doses that they found were actually delivered to areas outside the main field of radiation.
The average age of the women when they were first diagnosed with breast cancer was 54 (with a range of 34-74) and the average age when a second primary lung cancer was diagnosed was at 68 (range 46-90). Seventy percent of the lung cancers were diagnosed five or more years following radiotherapy for breast cancer, ranging from five to 26 years. The majority (91%) of the lung cancer cases were smokers, whereas 40% of the controls were smokers.
The average dose of radiotherapy during breast cancer treatment that had been delivered to the site of the lung tumor was 8.7 Gy, while it was 5.6 Gy to the comparable site in the women who had not developed lung cancer. Even though the absolute risk of developing a second lung cancer is tiny, the researchers demonstrated that among women who had survived breast cancer for at least five years, the relative risk of subsequently developing a lung cancer increased by 8.5% per delivered Gy to the lung.
"These results show that the risk of second lung cancer after radiotherapy in early breast cancer patients is associated with the delivered dose to the lung. It is, however, important to place the risk of getting a radiation-induced second lung cancer in a perspective that is balanced with the known benefits of radiotherapy in the adjuvant treatment of breast cancer. Post-operative radiotherapy in breast cancer patients decreases the likelihood of breast cancer recurrence and improves overall survival. The challenge for radiation oncologists is to reduce the delivered dose of radiotherapy in a way that minimizes the dose to the normal tissue to avoid radiation-induced malignancies, without compromising its efficacy in the cancerous breast tissue," said Grantzau.
"Furthermore, clinicians should be continually advising breast cancer patients to quit smoking in order to reduce their risk of developing lung cancer. It's important to emphasize that the risk of getting a tobacco-induced lung cancer is much higher than the risk of getting a radiation-induced second lung cancer,” she added.
"This research shows the importance of monitoring the safety of radiotherapy procedures so that we can use the information gained to achieve a good balance between the risks and benefits of a particular treatment. Reducing the radiation dose to normal tissue is always beneficial, and knowing the exact target and the best radiation dose will help to reduce any long-term side-effects of a therapy that research has long shown to be instrumental in helping to save the lives of women with breast cancer. Dr Grantzau's research suggests there is a small increased risk of lung cancer in the years after radiotherapy for breast cancer, particularly in women who smoke. This underlines the importance to women of not smoking, as this increases the risk of a range of diseases. We, as radiation oncologists, will continue to work to monitor and improve the safety and efficacy of our therapies,” noted President of ESTRO and a radiation oncologist at the Policlinico Universitario A. Gemelli, Rome, Italy, Professor Vincenzo Valentini.
